Reducing SBP Targets Below Current Guidelines Cuts Risk
Reducing SBP to 120 to 124 mm Hg linked to reduced risk of cardiovascular disease, all-cause mortality
FRIDAY, June 2, 2017 (HealthDay News) -- For adults with hypertension treated with antihypertensive medication, reducing systolic blood pressure (SBP) levels to 120 to 124 mm Hg is associated with reduced risk of cardiovascular disease and all-cause mortality, according to a review published online May 31 in JAMA Cardiology.
Joshua D. Bundy, M.P.H., from the Tulane University School of Public Health and Tropical Medicine in New Orleans, and colleagues examined the correlation of mean achieved SBP levels with the risk of cardiovascular disease and all-cause mortality in adults with hypertension. Data were included from 42 trials, with 144,220 patients.
The researchers observed linear associations between mean achieved SBP and risk of cardiovascular disease and mortality; the lowest risk was seen at 120 to 124 mm Hg. For randomized groups with a mean achieved SBP of 120 to 124 mm Hg, the hazard ratios for major cardiovascular disease were 0.71 compared with SBP of 130 to 134 mm Hg, 0.58 compared with SBP of 140 to 144 mm Hg, 0.46 compared with SBP of 150 to 154 mm Hg, and 0.36 compared with SBP of 160 mm Hg or more. The corresponding hazard ratios for all-cause mortality were 0.73, 0.59, 0.51, and 0.47, respectively.
"These findings support more intensive control of SBP among adults with hypertension," the authors write.